EUDA Health Holdings Limited announced details of a non-binding Memorandum of Understanding signed on July 15, 2026, with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. The collaboration aims to develop off-the-shelf cell therapies for oncology and wellness by combining GO POSB’s induced pluripotent stem cell platform and tumor organoid bank with SIIT’s Natural Killer cell engineering capabilities. EUDA intends to fund the joint program, facilitate commercialization, and support global market access subject to definitive agreements and regulatory approvals. The company operates in the healthcare distribution sector, focusing on wellness and non-invasive products in Asia.